Trial data shows AstraZeneca’s COVID-19 vaccine was highly effective
AstraZeneca announced today, that interim trial data has shown it’s COVID-19 vaccine candidate AZD1222, developed in collaboration with the University
Read moreAstraZeneca announced today, that interim trial data has shown it’s COVID-19 vaccine candidate AZD1222, developed in collaboration with the University
Read moreModerna announced its vaccine candidate against COVID-19 named mRNA-1273, has met Phase 3 study statistical criteria with a vaccine efficacy
Read morePfizer and BioNTech have announced their mRNA-based vaccine candidate for COVID-19, tested in a Phase 3 study involving 43,538 participants,
Read moreNovavax has announced the expansion of its Gaithersburg, Maryland campus to support global vaccine development through the addition of two
Read moreSanofi and GSK plan to make available to the Gavi lead COVAX Facility 200 million doses of their adjuvanted recombinant
Read moreEli Lilly and Company officially announced on Oct. 28, an initial deal with the U.S. government to supply 300,000 vials
Read moreAstraZeneca has confirmed that the U.S. FDA has authorised the resumption of Phase III clinical trials of the COVID-19 AZD1222
Read moreThe World Health Organization (WHO) and the Democratic Republic of Congo (DRC) government announced on June 25 that the second-largest
Read moreThe Chinese company Clover Biopharmaceuticals revealed the start of a randomized, double-blind, human stage Phase I placebo-controlled clinical study to
Read moreBritish pharmaceutical company AstraZeneca has reached a landmark $750 million agreement with Coalition for Epidemic Preparedness Innovation (CEPI) and the
Read more